MSL Consultant Podcast

I interview Drew McGregor, Vice President, Head of Medical Affairs Excellence & Sustainability at Bayer. We discuss: How to balance patient focus with commercial objectives How to reduce silos across the organisation What would pharma look like without a separate MA strategy?

Interview with Sue Giordano - Head of Field Medical at Axsome Therapeutics. We discuss: What types of data are available to medical affairs?  What is the first step when choosing the type of data to show impact (asking the right question) What else needs to be kept in mind (cross functional communication) Can you provide some examples of how data (and which type of data) can be used to show MA impact (MSLs and impact on diagnosis code examples - pilot it first before widespread roll out) What type of competencies need to be in place for MA to successfully utilize data to show their impact?  How can these competencies be developed (in house v external)

Carlos Eid from Novartis shares his expertise on: The stakeholder engagement Journey Creating a seamless customer journey Starting with the patient Developing customer intimacy The types of data to collect along this engagement journey to assess if course correction is required.

I interview Raquel Washington, Executive Director Value Evidence Lead-Novartis US Medical. Raquel shares her experience on: - how Medical Science Liaisons (MSLs) can own their development - the steps required to progress in their careers - where to find those opportunities to grow and how to build relationships with those people in your network who will advocate for your growth. Raquel has had an incredible career in pharma so far and shares specific examples from her own pharma career and some of the challenges she overcame to get to where she is today.